최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기Archives of pharmacal research : a publication of the Pharmaceutical Society of Korea, v.28 no.4, 2005년, pp.451 - 457
Joo Seong Soo (Department of Immunology, College of Pharmacy, Chung-Ang University) , Lee Do Ik (Department of Immunology, College of Pharmacy, Chung-Ang University)
Experimental studies have demonstrated that the triple combination of amantadine (A)/ ursodeoxycholic acid (UDCA, U)/ biphenyl dimethyl dicarboxylate (DDB, D) might have a preferential antiviral effect compared with that observed in interferon-induced antiviral signal pathways, such as those of 주제어
* AI 자동 식별 결과로 적합하지 않은 문장이 있을 수 있으니, 이용에 유의하시기 바랍니다.
Abdelmalek, M. F., Harrison, M. E., Gross, Jr. J. B., Poterucha, J. J., Gossard, A. A., Spivey, J. R., Rakela, J., and Lindor, K. D., Treatment of chronic hepatitis C with interferon with or without ursodeoxycholic acid: a randomized prospective trial. J. Clin. Gastroenterol, 26, 130-134 (1998)
Asmuth, D. M., Nguyen, H. H., Melcher, G. P., Cohen, S. H., and Pollar, R. B., Treatments for hepatitis B. Clin. Infect. Dis., 39, 1353-1362 (2004)
Beasley, R. P., Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer, 61, 1942-1956 (1988)
Bonkovsky, H. L., Therapy of hepatitis C: Other options. Hepatology, 26, S143-151 (1997)
Bose, S., Kar, N., Maitra, R., Didonato, J. A., and Banerjee, A. K., Temporal activation of $NF-\kappaB$ regulates an interferonindependent innate antiviral response against cytoplasmic RNA viruses. Proc. Natl. Acad. Sci. U.S.A., 100, 10890-10895 (2003)
Chiu, P. Y., Tang, M. H., Mak, D. H. F., Poon, M. K. T., and Ko, K. M., Hepatoprotective mechanism of schsandrin B: Role of mitochondrial glutathione antioxidant status and heat shock proteins. Free Radical Res., 35, 368-380 (2003)
Clercq, E. D., Antivirals and antiviral strategies. Nat. Rev. Microbiol., 2, 704-720 (2004)
Clercq, E. D., Perspectives for the treatment of hepatitis B virus infections. Int. J. Antimicrob. Ag., 12, 81-95 (1999)
Cotonat, T., Quiroga, J. A., Lopez-Alcorocho, J. M., Clouet, R., Pardo, M., Manzarbeitia, F., and Carreno, V., Piolt study of combination therapy with ribavirin and interferon alfa for the retreatment of chronic hepatitis B e antibody-positive patients. Hepatology, 31, 502-506 (2000)
Darnell, J. E. Jr., Kerr, I. M., and Stark, G. R., Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science, 264, 1415-1421 (1994)
Davey, S., State of the world's vaccines and immunization. Geneva: World Health Organisation, 76-82 (1996)
Fabris, P., Tositti, G.., Mazzella, G.., Zanetti, A. R., Nicolin, R., Pellizzer, G., Benedetti, P., and de Lalla, F., Effect of ursodeoxycholic acid administration in patients with acute viral hepatitis: a pilot study. Aliment. Pharm. Ther., 13, 1187- 1193 (1999)
Findor, J. A., Daruich, J. Z., and Bruch, I. E., Amantadine HCl alone and associated with recombinant alpha IFN 2a during a short term therapy in chronic HCV infection. Hepatology, 26:217A (1997)
Guidotti, L. G.., McClary, H., Loudis, J. M., and Chisari, F. V., Nitric oxide inhibits hepatitis B virus replication in the livers of transgenic mice. J. Exp. Med., 191, 1247-1252 (2000)
Hancke, J. L., Burgos, R., and Ahumada F., Schisandra chinensis (Turcz) Baill. Fitotherapia, 70, 451-471 (1999)
Huber, R., Hockenjos, B., and Blum, H. E., DDB treatment of patients with chronic hepatitis. Hepatology, 39, 1732-1733 (2004)
Koulentaki, M., Notas, G., Petinaki, E. Valatas, V., Mouzas, I. A., Castanas, E., and Kouroumalis, E. A., Nitric oxide and proinflammatory cytokines in acute hepatitis B. Eur. J. Int. Med., 15, 35-38 (2004)
Lindenmann, J., From interference to interferon: a brief historical introduction. Philos. T. Roy. Soc. B., 299, 3-6 (1982)
Locarnini, S. and Birch, C., Antiviral chemotherapy for chronic hepatitis B infection: lessons learned from treating HIVinfected patients. J. Hepatol., 30, 536-550 (1999)
Lowenstein, C. S., Dinerman, J. L., and Snyder, S. H., Nitric oxide: a physiologic messenger. Ann. Intern. Med., 120, 227- 237 (1994)
Neuman, M. G., Blendis, L. M., Shear, N. H., Malkiewicz, I. M., Ibrahim, A., Katz, G. G., Sapir, D., Halpern, Z., Brill, S., Peretz, H., Magazinik, S. M., and Konikoff, F. M., Cytokine network in nonresponding chronic hepatitis C patients with genotype 1: role of triple therapy inth interferon alpha, ribavirin, and ursodeoxycholate. Clin. Biochem., 34, 183-188 (2001)
Platania, L. C. and Fish, E. N., Signaling pathways activated by interferons. Exp. Hematol., 27, 1583-1592 (1999)
Reiss, C. S. and Komatsu, T., Does nitric oxide play a critical role in viral infection?, J. Virol., 72, 4547-4551 (1998)
Sells, M. A. and Chen, M. L., Acs, G.., Production of hepatitis B virus particles in HepG2 cells transfected with cloned hepatitis B virus DNA. Proc. Natl. Acad. Sci. U.S.A., 84, 1005-1009 (1987)
Stuyver, L. J., Lostia, S., and Adams, M. et al. Antiviral activities and cellular toxicities of modified 2,3-dideoxy-2,3-Didehydrocytidine analogues. Antimicrob. Agents Chemother., 3854-3860 (2002)
Trauner, M. and Graziadel, I. W., Mechanisms of action and therapeutic applications of ursodeoxycholic acid in chronic liver diseases. Aliment. Pharmacol. Ther., 13, 979-995 (1999)
Wharton, S. A., Belshe, R. B., Skehel, J. J., and Hay, A. J., Role of virion M2 protein in influenza virus uncoating: specific reduction in the rate of membrane fusion between virus and liposomes by amantadine. J. Gen. Virol., 75, 945-948 (1994)
Zhu, H., Zhao, H., Collins, C. D., Eckenrode, S. E., Run, Q., McIndoe, R. A., Crawford, J. M., Nelson, D. R., She, J. X., and Liu1, C., Gene expression association with interferon alpha antiviral activity in an HCV replicon cell line. Hepatology, 37, 1180-1188 (2003)
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
Free Access. 출판사/학술단체 등이 허락한 무료 공개 사이트를 통해 자유로운 이용이 가능한 논문
※ AI-Helper는 부적절한 답변을 할 수 있습니다.